Ruffo Frank 4
4 · Aclaris Therapeutics, Inc. · Filed Mar 14, 2022
Insider Transaction Report
Form 4
Ruffo Frank
Chief Financial Officer
Transactions
- Sale
Common Stock
2022-03-10$15.55/sh−12,823$199,335→ 201,883 total
Footnotes (2)
- [F1]Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2022 and March 2, 2022 pursuant to preexisting sell-to-cover elections.
- [F2]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.22 to $16.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.